Acadian Asset Management LLC Buys 63,901 Shares of Anika Therapeutics Inc. $ANIK

Acadian Asset Management LLC increased its stake in shares of Anika Therapeutics Inc. (NASDAQ:ANIK) by 13.4% during the 1st quarter, Holdings Channel.com reports. The fund owned 539,614 shares of the biotechnology company’s stock after purchasing an additional 63,901 shares during the quarter. Acadian Asset Management LLC’s holdings in Anika Therapeutics were worth $8,107,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of ANIK. Jane Street Group LLC grew its position in Anika Therapeutics by 12.6% during the 4th quarter. Jane Street Group LLC now owns 27,416 shares of the biotechnology company’s stock worth $451,000 after acquiring an additional 3,065 shares during the last quarter. Ameriprise Financial Inc. grew its position in Anika Therapeutics by 81.3% during the 4th quarter. Ameriprise Financial Inc. now owns 46,093 shares of the biotechnology company’s stock worth $759,000 after acquiring an additional 20,663 shares during the last quarter. BNP Paribas Financial Markets grew its position in Anika Therapeutics by 408.6% during the 4th quarter. BNP Paribas Financial Markets now owns 14,448 shares of the biotechnology company’s stock worth $238,000 after acquiring an additional 11,607 shares during the last quarter. Bank of America Corp DE grew its position in Anika Therapeutics by 10.9% during the 4th quarter. Bank of America Corp DE now owns 38,218 shares of the biotechnology company’s stock worth $629,000 after acquiring an additional 3,758 shares during the last quarter. Finally, Cubist Systematic Strategies LLC grew its position in Anika Therapeutics by 64.1% during the 4th quarter. Cubist Systematic Strategies LLC now owns 11,990 shares of the biotechnology company’s stock worth $197,000 after acquiring an additional 4,682 shares during the last quarter. 91.53% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Barrington Research reduced their price target on Anika Therapeutics from $19.00 to $15.00 and set an “outperform” rating on the stock in a research report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company. According to data from MarketBeat.com, Anika Therapeutics has a consensus rating of “Strong Buy” and a consensus price target of $18.00.

Anika Therapeutics Stock Performance

Shares of ANIK stock opened at $8.67 on Friday. The firm has a market cap of $125.02 million, a P/E ratio of -2.09 and a beta of 0.63. Anika Therapeutics Inc. has a fifty-two week low of $7.87 and a fifty-two week high of $26.00. The business’s 50 day moving average price is $9.59 and its 200-day moving average price is $12.13.

About Anika Therapeutics

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.